Wall Street Zen cut shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) from a hold rating to a sell rating in a report issued on Sunday,Wall Street Zen reports.
TRDA has been the subject of several other research reports. Weiss Ratings downgraded Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th. UBS Group reissued a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. HC Wainwright reissued a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. Finally, Roth Capital restated a “buy” rating and issued a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $17.75.
Read Our Latest Research Report on TRDA
Entrada Therapeutics Price Performance
Shares of TRDA opened at $4.53 on Friday. The business has a fifty day moving average of $6.04 and a 200 day moving average of $8.72. Entrada Therapeutics has a one year low of $4.11 and a one year high of $16.45. The firm has a market capitalization of $176.40 million, a P/E ratio of -1.14 and a beta of -0.19.
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. Analysts expect that Entrada Therapeutics will post -4.03 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Kush Parmar sold 92,444 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $7.00, for a total value of $647,108.00. Following the sale, the director directly owned 2,691,337 shares in the company, valued at $18,839,359. This trade represents a 3.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $7.41, for a total value of $1,426,425.00. Following the transaction, the insider owned 3,913,952 shares in the company, valued at approximately $29,002,384.32. This represents a 4.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 714,013 shares of company stock worth $5,111,237. Insiders own 9.49% of the company’s stock.
Institutional Investors Weigh In On Entrada Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming bought a new stake in shares of Entrada Therapeutics during the second quarter valued at about $37,000. ADAR1 Capital Management LLC bought a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at about $114,000. Deutsche Bank AG purchased a new stake in Entrada Therapeutics in the 2nd quarter worth $195,000. Ieq Capital LLC purchased a new stake in shares of Entrada Therapeutics in the second quarter worth approximately $218,000. Finally, Odyssean LLC bought a new position in shares of Entrada Therapeutics during the second quarter valued at approximately $230,000. Institutional investors and hedge funds own 86.39% of the company’s stock.
Entrada Therapeutics Company Profile
Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.
Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.
Featured Articles
- Five stocks we like better than Entrada Therapeutics
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
